Introduction
============

COPD has a major impact on individuals and on the society.[@b1-copd-12-1047] Exacerbations represent a major component of COPD-related burden, during both the acute phase and chronic management. They are important causes of unscheduled physician visits and hospital admissions.[@b2-copd-12-1047]--[@b4-copd-12-1047] There is a wide range of disease severity among hospitalized patients with exacerbations of COPD (ECOPD), ranging from brief emergency room (ER) admission to prolonged hospital stay and death. Although most exacerbations are managed at home, patients visiting ERs are often hospitalized, which is in part due to difficulties in predicting outcome based on initial observations. Several studies have aimed at developing accurate assessment strategies to help caregivers identifying patients at risk of worsening.[@b5-copd-12-1047]--[@b7-copd-12-1047] A clinical risk score based on underlying dyspnea severity, age and clinical signs of severity was proposed in 2008 and subsequently modified in 2014 with the inclusion of cardiovascular comorbidities.[@b8-copd-12-1047],[@b9-copd-12-1047] This score categorizes patients into 3 risk categories (low, intermediate and high risk) with acceptable performance to predict in-hospital mortality for patients visiting ERs or hospitalized for ECOPD.[@b8-copd-12-1047] Recently, plasma biomarkers are of increasing interest as a means to characterize disease severity and prognosis in this context.[@b10-copd-12-1047]--[@b12-copd-12-1047] Mid-regional pro-adrenomedullin (MR-proADM) and copeptin have been investigated as markers of long-term outcomes of COPD patients,[@b11-copd-12-1047],[@b13-copd-12-1047] but not specifically for the prediction of short-term outcomes of COPD exacerbations. Therefore, the current study aimed at determining whether the prognostic value of MR-proADM and/or copeptin added to the abovementioned clinical risk score could accurately predict short-term outcomes of COPD exacerbations.

Patients and methods
====================

Study design
------------

This prospective blinded observational study was conducted in 20 centers across France. Centers were asked to prospectively include patients visiting their ER between November 2011 and November 2014 with a certain or probable diagnosis of COPD exacerbation. Patients were followed up until 30 days after inclusion. The protocol was approved by the Comité de Protection des Personnes Ile de France 1 (2012-A01237-36). Written informed consent was obtained from all patients. The study was registered on [ClinicalTrials.gov](http://ClinicalTrials.gov): NCT01857947.

Inclusion and non-inclusion criteria
------------------------------------

Patients were included if they presented with a probable or certain ECOPD, as defined by the appearance or worsening of dyspnea in a patient with known COPD or risk factors for COPD (age \>40 years and current or past cumulative tobacco consumption of \>10 pack-years) and no evidence for an alternative diagnosis:[@b14-copd-12-1047] specifically, patients were not included when the investigator judged that the predominant diagnosis was or was likely to be pneumonia, pulmonary embolism, congestive heart failure and pneumothorax or when the predominant underlying respiratory disease was asthma, bronchiectasis, congestive heart failure, thromboembolic disease or restrictive respiratory insufficiency. Patients requiring immediate intensive care unit monitoring and/or noninvasive or invasive ventilation were not included.

Data collection
---------------

The following data were collected: age, sex, comorbid conditions, smoking history, known diagnosis of COPD, chronic bronchitis or emphysema, age at first respiratory symptoms, usual severity of dyspnea at steady state using the modified Medical Research Council scale, self-reported number of emergency visits and hospitalizations during the past 6 months and maintenance treatments. The history of the current exacerbation, dyspnea grade at entry and clinical signs of severity, as well as results of routine venous and arterial blood sampling and chest X-ray, were recorded. Diagnostic procedures and treatments in the hospital were collected. Upon discharge, the local coordinating respiratory physician was requested to provide his/her final conclusions regarding the diagnosis (confirmed ECOPD or alternative diagnosis) and the certain or probable etiology of the exacerbation.

Blood sample for MR-proADM and copeptin plasma level determination
------------------------------------------------------------------

All blood samples were collected on patient's admission and were stored for subsequent blinded determination (Supplementary materials).

Study end points
----------------

The primary end point was a composite outcome defined by death, transfer to the intensive care unit or new exacerbation requiring hospitalization or ER visit within 30 days after enrollment. The main secondary end point was the same composite variable within 7 days of enrollment.

Statistical analysis
--------------------

Sample size was calculated assuming an estimated prevalence of the primary end point of 30% and a mean (standard deviation) of 0.8 (0.5) nmol/L for MR-proADM levels.[@b11-copd-12-1047] According to statistical simulations on the basis of a 2-sided comparison at 5% significance level with 80% power, 250 patients would allow to estimate an odds ratio (OR) of 2.1 between risk categories.

The analysis included patients in whom MR-proADM and copeptin plasma level, variables involved in the primary composite end point and variables of the 2008 clinical score[@b8-copd-12-1047] were available. Continuous variables are presented as medians (interquartile range \[IQR\]) and discrete variables as percentage. Qualitative variables were compared using the chi-square test or the Fisher's exact test (as appropriate). Quantitative variables were analyzed by Student's *t*-test or by the nonparametric Wilcoxon--Mann--Whitney test (if normality could not be established). Comparison of 3 or more means was performed by ANOVA or Kruskal--Wallis test, as appropriate. The Spearman correlation was used to evaluate the relationship between MR-proADM and clinical risk score category and clinical/biological variables.

All hypothesis tests were 2-sided at the 5% level of significance. Statistical analyses were performed by using ad hoc routines implemented in R 3.2.0 software.

A 4-step analytical plan was applied to explore the primary objective of the study. The first step was the comparison of MR-proADM levels between patients who met and those who did not meet the primary end point. Second, receiver operating characteristic (ROC) curves were built using the ROCR package[@b15-copd-12-1047] to assess the global performance of MR-proADM to predict the occurrence of the primary end point and to define the optimal cutoff. A bootstrap method was used to calculate the 95% confidence interval (CI) of areas under the ROC curves, sensitivities and specificities. Third, the 2008 clinical risk score[@b8-copd-12-1047] was calculated and the patients were allocated to the risk categories. Finally, a multivariate logistic regression analysis assessed the predictive performance of the MR-proADM plasma levels after adjustment on the 2008 clinical score. The same strategy was followed for copeptin.

Results
=======

Population
----------

From the 379 patients eligible for inclusion during the study period, 277 were finally included in the analyses ([Figure 1](#f1-copd-12-1047){ref-type="fig"}). Among them, 247 (89%) were known to have a COPD, 142 (51%) had a 4 or 5 baseline dyspnea grade and 137 (50%) had at least 1 ECOPD in the previous year ([Table 1](#t1-copd-12-1047){ref-type="table"}).

Occurrence of the primary and secondary end points
--------------------------------------------------

The primary end point occurred in 66 (24%) patients: 14 died, 25 were transferred to the intensive care unit and 35 had a new COPD exacerbation in the 30 following days (8 patients encountered 2 events). There was no difference between patients with and without occurrence of the primary end point in terms of signs of severity (as used in the 2008 risk score) and treatments administered in the ER ([Table 2](#t2-copd-12-1047){ref-type="table"}). However, respiratory rate and PaCO~2~ was higher in patients in whom the primary end point occurred. The secondary end point occurred in 34 (12.3%) patients ([Table S1](#SD2-copd-12-1047){ref-type="supplementary-material"}).

MR-proADM and clinical risk score
---------------------------------

In the whole population, MR-proADM concentration was 0.87 nmol/L (0.67--1.15). In patients who met and did not meet the primary end point, it was 1.02 nmol/L (0.77--1.48) and 0.83 nmol/L (0.63--1.07), respectively (*P*=0.0009; [Figure 2](#f2-copd-12-1047){ref-type="fig"}, [Table 3](#t3-copd-12-1047){ref-type="table"}). In patients who met and in those who did not meet the secondary end point, MR-proADM was 1.18 nmol/L (0.81--1.86) and 0.84 nmol/L (0.67--1.11), respectively (*P*=0.003; [Table S1](#SD2-copd-12-1047){ref-type="supplementary-material"}).

Using the clinical risk score, 44 (16%) patients were classified as low risk, 113 (41%) patients as intermediate risk and 120 (43%) as high risk. MR-proADM levels increased with increasing risk category: 0.74 nmol/L (0.57--0.89), 0.83 nmol/L (0.62--1.12) and 0.95 nmol/L (0.75--1.29) for the low-, intermediate- and high-risk categories, respectively (*P*\<0.001). The correlation between MR-proADM and the clinical risk score category was significant (Spearman *R* value =0.27; *P*\<0.0001). The correlations between MR-proADM and the main clinical and arterial blood gases variables are given in [Table S2](#SD3-copd-12-1047){ref-type="supplementary-material"}.

MR-proADM for the prediction of primary and secondary end points: multivariate models adjusting for clinical risk score
-----------------------------------------------------------------------------------------------------------------------

MR-proADM was independently associated with the primary end point (OR, 1.65; 95% CI, 1.10--2.48; *P*=0.015) and with the secondary end point (OR, 1.99; 95% CI, 1.27--3.11; *P*=0.002; [Table 4](#t4-copd-12-1047){ref-type="table"}).

With a cutoff of 1.13 nmol/L, MR-proADM predicted the occurrence of the primary end point with a sensitivity of 46% (95% CI, 33%--58%) and a specificity of 79% (95% CI, 74--84) (area under the ROC curve, 0.64 \[95% CI, 0.55--0.71\]; [Figure 3](#f3-copd-12-1047){ref-type="fig"}).

Regarding the secondary end point, the area under the ROC curve was of 0.65 (95% CI, 0.53--0.75) and the MR-proADM cutoff value of 1.13 nmol/L provided a sensitivity of 56% (95% CI, 38%--74%) and a specificity of 77% (95% CI, 72--83; [Figure S1A](#SD1-copd-12-1047){ref-type="supplementary-material"}). Adjusting for the clinical risk score did not improve the diagnostic performance (area under the ROC curve of 0.68 \[95% CI, 0.58--0.77\]). For both primary and secondary end points, similar features were obtained when MR-proADM and clinical risk score were associated ([Figures 3](#f3-copd-12-1047){ref-type="fig"} and [S1A](#SD1-copd-12-1047){ref-type="supplementary-material"}).

Copeptin for the prediction of primary and secondary end point: multivariate models adjusting for clinical risk score
---------------------------------------------------------------------------------------------------------------------

In the whole population, copeptin concentration was 13.06 pmol/L (5.95--33.43). Copeptin levels were similar in patients who met or did not meet the primary end point (*P*=0.23; [Table 2](#t2-copd-12-1047){ref-type="table"}) but significantly higher in patients who met the secondary end point (*P*=0.004; [Table S1](#SD2-copd-12-1047){ref-type="supplementary-material"}). Accordingly, copeptin was not associated with the primary end point (OR, 1.04; 95% CI, 0.99--1.09; *P*=0.09) but was independently associated with the secondary end point (OR, 1.08; 95% CI, 1.02--1.14; *P*=0.006; [Table 5](#t5-copd-12-1047){ref-type="table"}). With a cutoff of 37.5 pmol/L, copeptin predicted the occurrence of the secondary end point with a sensitivity of 47% (95% CI, 29%--65%) and a specificity of 82% (95% CI, 77--87; area under the ROC curve, 0.65; 95% CI, 0.54--0.76). Similar predictive properties were observed when copeptin and clinical risk score were associated ([Figure S1B](#SD1-copd-12-1047){ref-type="supplementary-material"}).

Discussion
==========

This prospective multicenter study is the first to concurrently assess the properties of MR-proADM and copeptin to predict short-term outcomes of patients visiting the ERs for an ECOPD, accounting for the clinical risk category. High levels of MR-proADM but not copeptin were significantly associated with worse outcomes at 30 days, even after adjustment for clinical risk category. The analysis of ROC curves found that MR-proADM, alone or in combination with the clinical risk category, was a moderate strong predictor of short-term outcomes. Both MR-proADM and copeptin were associated with 7-day outcomes in both univariate and multivariate analyses adjusting for clinical risk category, again with moderate strong discriminative properties.

Prognostic value of MR-proADM
-----------------------------

Several investigations highlighted the interest of plasma biomarkers and their combination with clinical features to improve risk stratification in various acute respiratory conditions such as COPD exacerbations or community-acquired pneumonia.[@b16-copd-12-1047]--[@b20-copd-12-1047] MR-proADM is a promising biomarker[@b21-copd-12-1047]--[@b23-copd-12-1047] that has been actively investigated as a tool to improve risk stratification in COPD patients.[@b11-copd-12-1047],[@b18-copd-12-1047],[@b24-copd-12-1047] During COPD exacerbations, MR-proADM levels increase,[@b11-copd-12-1047],[@b24-copd-12-1047] suggesting that it could be of special interest in that specific context. In the current study, we confirmed previous reports,[@b11-copd-12-1047],[@b24-copd-12-1047] showing that MR-proADM levels on admission are higher in patients with subsequently worse outcomes. Even after adjustment for the clinical risk score category, MR-proADM remained independently associated with outcomes at 7 and 30 days. However, MR-proADM levels were only a moderate strong predictor of short-term outcomes. In contrast, MR-proADM has previously been established as a powerful predictor of long-term risk of death in COPD patients.[@b18-copd-12-1047],[@b24-copd-12-1047],[@b25-copd-12-1047] One hypothesis to explain this discrepancy is that the value of MR-proADM as a predictor of short-term outcomes during exacerbations could be influenced by the etiology/phenotype of the event,[@b26-copd-12-1047] the severity/phenotype of the underlying disease and/or the presence of comorbidities, all of which being known determinants of outcomes.[@b14-copd-12-1047],[@b27-copd-12-1047] Our study was not designed to test this possibility: a systematic process was not used to investigate the underlying COPD phenotype, exacerbations' etiologies and underlying mechanisms and the sample size would not be sufficient to perform reliable subgroup analyses.

Our findings are partly in line with the study by Stolz et al,[@b11-copd-12-1047] in which the relationship between MR-proADM levels and long-term outcomes (survival, hospital admission) appeared stronger than with short-term (in-hospital) mortality in patients with COPD exacerbations. The levels of MR-proADM observed at exacerbation in that study were comparable to what we found. Interestingly, the frequency of comorbid heart disease (45%) was markedly higher than in our study (10%), which may help explaining the difference in prognostic value of the biomarker. Along the same line, in our study but not in that of Stolz et al,[@b11-copd-12-1047] investigators were informed to exclude patients with suspected heart failure or pneumonia. This may be of importance to explain the lower short-term prognostic value in our study compared to that of Stolz et al,[@b11-copd-12-1047] since MR-proADM has been associated with cardiovascular stress and infection.[@b28-copd-12-1047]

While MR-proADM may be a useful marker of long-term prognosis in COPD,[@b11-copd-12-1047],[@b25-copd-12-1047] it appears unlikely to be a powerful predictor of short-term outcomes in acute COPD-related events, at least in patients with relatively "pure" exacerbations, ie, excluding those in whom heart failure or pneumonia could be involved. In this regard, our findings are somehow similar to a recent study showing that in patients with acute dyspnea admitted in the ERs, measurements of pro-hormone type biomarkers had only a low added value to clinical signs for the prediction of poor outcome.[@b29-copd-12-1047]

Prognostic value of copeptin
----------------------------

The performance of copeptin in predicting short- and long-term mortality in COPD patients with exacerbation was reported previously.[@b13-copd-12-1047],[@b30-copd-12-1047],[@b31-copd-12-1047] In our study, while copeptin levels increased with the clinical risk score, it failed to predict the composite primary outcome, in contrast to what we found with MR-proADM. However, copeptin levels were significantly higher in our patients who met the 7-day composite end point. Interestingly, we found that the best cutoff in copeptin level predicting this secondary end point was very close to what has been already reported.[@b13-copd-12-1047] These findings suggest that copeptin would rather be considered as a marker of early outcome. Nevertheless, as MR-proADM, its performance to predict 7-day outcomes was rather low.

Strengths and limitations of the study
--------------------------------------

The main strength of the current study is the prospective multicenter design, enhancing the generalizability and reliability of results. Another strength is the use of a composite end point, better reflecting the potential complications that may affect a COPD patient after ER discharge.

Some limitations have to be acknowledged. First, patients were only followed up until day 30, since our main interest was to develop a combined clinical and biological tool easily available in the ER to help clinicians in the decision-making process in terms of orientation and triage. Second, the prevalence of the primary outcome was slightly lower than expected, which decreases the power of the analyses. However, although this might make it more difficult to achieve statistical significance, it would not change the magnitude of associations. Third, the severity of COPD in our population was not easily comparable to other studies since lung function measurements were inconsistently available. However, half of the patients had a baseline dyspnea score of 4 or 5, reflecting severe disease.

Conclusion
==========

In COPD patients admitted to the ER for exacerbations, MR-proADM was significantly associated with the risk of poor outcome at 7 and 30 days, even after adjustment for the clinical risk category. However, the predictive value was relatively modest, as assessed by the area under the ROC curve. Copeptin was only associated with 7-day outcomes. Additional studies are required to further explore how these biomarkers could be integrated in predictive rules aiming at identifying patients at risk of poor early outcomes.

Supplementary materials
=======================

Patients and methods
--------------------

Blood sample for mid-regional pro-adrenomedullin (MR-proADM) and copeptin plasma level determination.

All blood samples were collected in plastic tubes containing ethylenediamine tetra-acetic acid, and plasma was stored at −20°C in plastic freezer vials. MR-proADM was measured using an automated sandwich chemiluminescence immunoassay on the KRYPTOR system (BRAHMS AG, Hennigsdorf/Berlin, Germany). The lower detection limit of the assay was 0.05 nmol/L, and the functional assay sensitivity was 0.25 nmol/L. The technicians processing the blood samples were blinded from any patient data. Copeptin was measured using 50 μL of ethylenediamine tetra-acetic acid plasma by a new sandwich immunoluminometric assay employing 2 polyclonal antibodies to amino acids 132--164 of preprovasopressin (C-terminal portion of pro-arginine-vasopressin by luminescence immunoassay; BRAHMS AG). The lower detection limit of the assay was 0.69 pmol/L, and the functional assay sensitivity was 1.08 pmol/L.

###### 

ROC curves showing the performance of the plasma level of MR-proADM or MR-proADM (**A**) associated with clinical risk score and of copeptin or copeptin (**B**) associated with clinical score to predict the occurrence of the secondary end point.

**Abbreviations:** MR-proADM, mid-regional pro-adrenomedullin; ROC, receiver operating characteristic.

###### 

Characteristics and outcomes of patients meeting or not meeting the secondary (7-day) outcome

  Characteristics                         All patients          Secondary outcome     *P*-value             
  --------------------------------------- --------------------- --------------------- --------------------- --------
  Increased/recent symptoms, n (%)                                                                          
   Cough                                  204 (74)              24 (71)               180 (74)              0.79
   Expectoration abundance                144 (52)              20 (59)               124 (51)              0.53
   Sputum purulence                       94 (34)               13 (39)               81 (34)               0.66
  Signs of severity, n (%)                                                                                  
   0                                      80 (29)               7 (21)                73 (30)               0.31
   1--2                                   152 (55)              19 (60)               133 (55)              
   \>3                                    44 (16)               8 (23)                36 (15)               
   Cyanosis                               48 (17)               7 (21)                41 (17)               0.78
   Neurological impairment                6 (2)                 2 (6)                 4 (2)                 0.16
   Lower limb edema                       53 (19)               7 (21)                46 (19)               1
   Asterixis                              14 (5)                4 (12)                10 (4)                0.08
   Use of accessory inspiratory muscles   158 (57)              23 (68)               135 (56)              0.26
   Expiratory use of abdominal muscles    109 (39)              17 (50)               92 (38)               0.25
  Physiological variables                                                                                   
   SAP, mmHg                              142 (123--160)        145 (121--177)        142 (123--160)        0.41
   DAP, mmHg                              79 (68--90)           79 (70--96)           79.0 (68--90)         0.18
   Respiratory rate, min^−1^              26 (22--30)           29 (24--32)           26 (21--30)           0.17
   Heart rate, min^−1^                    95 (84--108)          91 (78--106)          96 (84--109)          0.28
   SpO~2~, %                              93 (90--96)           94 (91--97)           93 (90--96)           0.25
  Clinical risk score, n (%)                                                                                
   Low risk                               43 (16)               2 (6)                 41 (17)               0.15
   Intermediate risk                      113 (41)              13 (38)               100 (41)              
   High risk                              120 (43)              19 (56)               101 (42)              
  Blood gases                                                                                               
   pH                                     7.39 (7.34--7.42)     7.37 (7.33--7.38)     7.40 (7.36--7.43)     0.0006
   PaCO~2~, mmHg                          46 (39--56)           55 (43--64)           46 (39--55)           0.011
   PaO~2~, mmHg                           68 (56.0--86)         72.5 (60--85)         67 (56--85)           0.64
   Lactate, mmol/L                        1.2 (1.0--1.8)        1.3 (0.9--1.7)        1.2 (1.0--1.8)        0.78
  Treatments in ER, n (%)                                                                                   
   Short-term β2-agonists                 244 (88.4)            31 (91.2)             213 (88.0)            0.80
   Anticholinergic agents                 227 (82.2)            27 (79.4)             200 (82.6)            0.82
   Oral corticosteroids                   27 (9.8)              3 (8.8)               24 (9.9)              1
   Oxygen therapy                         124 (44.9)            15 (44.1)             109 (45.0)            1
   Noninvasive ventilation                45 (16.3)             8 (23.5)              37 (15.3)             0.33
  Biomarkers                                                                                                
   MR-proADM, nmol/L                      0.87 (0.67--1.15)     1.18 (0.81--1.86)     0.84 (0.67--1.11)     0.003
   Copeptin, pmol/L                       13.06 (5.93--33.52)   30.12 (7.61--78.01)   11.78 (5.84--30.82)   0.004

**Abbreviations:** ER, emergency room; MR-proADM, mid-regional pro-adrenomedullin; SAP, systolic arterial pressure; DAP, diastolic arterial pressure.

###### 

Correlation between MR-proADM and clinical and biological variables (Spearman correlation)

  Variables                            Spearman coefficient   *P*-value
  ------------------------------------ ---------------------- -----------
  Clinical                                                    
   Systolic arterial pressure, mmHg    \<0.0001               0.99
   Diastolic arterial pressure, mmHg   −0.09                  0.07
   Heart rate, min^−1^                 −0.02                  0.73
   Respiratory rate, min^−1^           0.11                   0.05
   Temperature, °C                     0.25                   \<0.0001
   SpO~2~, %                           −0.1                   0.05
  Arterial blood gases                                        
   pH                                  −0.08                  0.13
   PaCO~2~, mmHg                       0.02                   0.72
   PaO~2~, mmHg                        −0.07                  0.17
   Lactate, mmol/L                     0.2                    \<0.05

**Abbreviation:** MR-proADM, mid-regional pro-adrenomedullin.

The study was an investigator-initiated study primarily funded by Thermo Scientific Biomarkers (formerly BRAHMS AG), Hennigsdorf, Germany, which provided all reagents gratis and, through an unrestricted research grant, funded all shipment costs of blood samples to the central biomarker testing facility at University Hospital Pitié-Salpêtrière. Drs Martin Dres, Nicolas Roche, Pierre Hausfater, Thomas Similowski, Jean-Marc Treluyer and Patrick Plasisance are the members of the UTAPE Scientific Committee. The list of the UTilité de la pro-Adrénomédulline comme facteur Prédictif d'évolution des Exacerbations de BPCO (UTAPE) study investigators is as follows: Patrick Plaisance (Lariboisiere Hospital, Paris), Arnaud Martinage (CHU Nantes), Nicolas Fraimout (CHU Nice), Pierre-Géraud Claret (Hôpital Carrémeau, Nîmes), Karim Tazarourte (CH Marc Jacquet, Melun), Eric Roupie (CHU Caen), Patrick Ray (Tenon Hospital, Paris), Paul Gayol (Hôpitaux Univer-sitaires de Strasbourg -- Hôpital Civil), Philippe Sattonnet (Hôpital Bel-Air CHR Metz-Thionville), Fatima Rayeh (CHU Poitiers), Dominique Savary (CHR Annecy), Bertrand Renaud (CHU Cochin, Paris), Mehdi Khellaf (CHU Henri Mondor, Créteil) and Sébastien Beaune (CHU Ambroise Paré, Boulogne Billancourt).
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![MR-proADM plasma level according to the primary end point and to each outcome of interest at day 30: mortality, ICU transfer and new exacerbation (ECOPD) requiring hospitalization.\
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###### 

Characteristics of the population

  Characteristics                                                 n=277
  --------------------------------------------------------------- -------------
  Demographic description                                         
   Age, years                                                     69 (62--78)
   Male, n (%)                                                    179 (65)
   Body mass index, kg⋅m^−2^                                      25 (21--41)
   Current smokers, n (%)                                         114 (42)
   Cumulative smoking consumption, pack-years                     47 (31--60)
   Ex-smokers, n (%)                                              135 (51)
   Known COPD, n (%)                                              247 (89)
   Institutionalization, n (%)                                    20 (7)
  Baseline dyspnea grade, n (%)                                   
   1                                                              12 (4)
   2                                                              49 (18)
   3                                                              74 (27)
   4                                                              70 (25)
   5                                                              72 (26)
  Hospitalization for COPD exacerbation in the last year, n (%)   
   0                                                              138 (50)
   1                                                              51 (19)
   2                                                              47 (17)
   \>3                                                            39 (14)
  Usual maintenance treatment, n (%)                              
   Short-acting β2-agonists                                       145 (52)
   Anticholinergic agents                                         115 (42)
   Inhaled corticosteroids                                        58 (21)
   Oral corticosteroids                                           43 (15)
   Long-term oxygen therapy                                       67 (24)
   Noninvasive ventilation                                        24 (9)
  Comorbidities, n (%)                                            
   Ischemic heart disease                                         47 (21)
   Chronic left ventricular failure                               23 (10)
   Diabetes mellitus                                              50 (22)
   Chronic renal failure                                          17 (8)

**Note:** Data are expressed as median (IQR) or n (%).

**Abbreviation:** IQR, interquartile range.

###### 

Initial presentation and management according to the occurrence of the primary outcome

  Patient's characteristics               All patients (n=277)   Primary outcome       *P*-value             
  --------------------------------------- ---------------------- --------------------- --------------------- --------
  Increased/recent symptoms, n (%)                                                                           
   Cough                                  205 (74)               46 (70)               159 (75)              0.45
   Expectoration abundance                145 (52)               37 (56)               108 (51)              0.61
   Sputum purulence                       95 (34)                21 (32)               74 (35)               0.76
  Signs of severity, n (%)                                                                                   
   0                                      81 (29)                16 (24)               65 (31)               0.32
   1--2                                   152 (55)               36 (54)               116 (55)              
   \>3                                    44 (16)                14 (21)               30 (14)               
   Cyanosis                               48 (17)                13 (20)               35 (17)               0.69
   Neurological impairment                6 (2)                  3 (4)                 3 (1)                 0.15
   Lower limb edema                       53 (19)                15 (23)               38 (18)               0.50
   Asterixis                              14 (5)                 5 (8)                 9 (4)                 0.33
   Use of accessory inspiratory muscles   158 (57)               41 (62)               117 (56)              0.42
   Expiratory use of abdominal muscles    109 (39)               30 (46)               79 (37)               0.31
  Physiological variables                                                                                    
   Systolic arterial pressure, mmHg       142 (123--160)         147 (122--170)        140 (123--157)        0.19
   Diastolic arterial pressure, mmHg      79 (68--90)            83 (71--94)           79 (67--89)           0.017
   Respiratory rate, min^−1^              26 (22--30)            29 (24--32)           26 (20--30)           0.032
   Heart rate, min^−1^                    95 (84--108)           94 (80--108)          96 (84--108)          0.70
   SpO~2~, %                              93 (90--96)            94 (90--96)           93 (90--96)           0.59
  Clinical risk score, n (%)                                                                                 
   Low risk                               44 (16)                7 (11)                37 (18)               0.15
   Intermediate risk                      113 (41)               24 (36)               89 (42)               
   High risk                              120 (43)               35 (53)               85 (40)               
  Blood gases                                                                                                
   pH                                     7.39 (7.34--7.43)      7.36 (7.30--7.41)     7.40 (7.35--7.44)     0.001
   PaCO~2~, mmHg                          46 (39--56)            52 (42--65)           46 (39--55)           0.005
   PaO~2~, mmHg                           68 (56--86)            68 (59.5--90)         67 (55--84)           0.28
   Lactate, mmol/L                        1.2 (1.0--1.8)         1.1 (0.9--1.5)        1.3 (1.0--2.0)        0.11
  Treatments administered in ER, n (%)                                                                       
   Antibiotics                            115 (41)               32 (48)               83 (39)               0.08
   Short-acting β2-agonists               245 (88)               59 (89)               186 (88)              0.96
   Anticholinergic agents                 228 (82)               54 (82)               174 (82)              0.99
   Oral corticosteroids                   27 (9)                 7 (11)                20 (9)                0.98
   Oxygen therapy                         125 (55)               33 (50)               92 (44)               0.44
   Noninvasive ventilation                45 (16)                13 (20)               32 (15)               0.50
  Biomarkers                                                                                                 
   MR-proADM, nmol/L                      0.87 (0.67--1.15)      1.02 (0.77--1.48)     0.83 (0.63--1.07)     0.0009
   Copeptin, pmol/L                       13.06 (5.95--33.43)    14.71 (6.25--40.13)   12.71 (5.89--31.08)   0.23

**Notes:** Primary outcome was a composite outcome defined by death, transfer to intensive care unit or new exacerbation requiring hospitalization or ER visit within 30 days after enrollment. Data are expressed as median (IQR) or n (%).

**Abbreviations:** ER, emergency room; IQR, interquartile range; MR proADM, mid-regional pro-adrenomedullin.

###### 

Occurrence of the primary and secondary outcomes according to the clinical risk score and MR-proADM

  Biomarkers and outcomes          Clinical risk score   *P*-value             MR-proADM             *P*-value                                           
  -------------------------------- --------------------- --------------------- --------------------- ----------- ------------------- ------------------- --------
  MR-proADM, nmol/L                0.74 (0.57--0.89)     0.83 (0.62--1.12)     0.95 (0.75--1.29)     \<0.0001    0.75 (0.58--0.90)   1.49 (1.26--1.99)   --
  Copeptin, pmol/L                 9.66 (3.53--27.16)    12.43 (6.35--33.62)   17.66 (6.38--33.62)   0.013       --                  --                  --
  **At day 30**                                                                                                                                          
   Death, n (%)                    2 (4.5)               3 (2.7)               9 (7.5)               0.28        8 (3.9)             6 (8.1)             0.013
   ICU transfer, n (%)             2 (4.7)               9 (8.0)               14 (11.9)             0.37        11 (5.5)            14 (19.2)           0.001
   New ECOPD, n (%)                4 (9.3)               14 (12.5)             17 (5.8)              0.62        22 (11.1)           13 (18.6)           0.17
  **Primary end point, n (%)**     7 (15.9)              24 (21.2)             35 (29.2)             0.15        36 (17.7)           30 (40.5)           0.0002
  **At day 7**                                                                                                                                           
   Death, n (%)                    0 (−)                 0 (−)                 6 (5.0)               0.028       2 (1.0)             4 (5.4)             0.046
   ICU transfer, n (%)             1 (2.3)               8 (7.1)               12 (10.0)             0.27        9 (4.5)             12 (16.2)           0.002
   New ECOPD, n (%)                1 (2.3)               6 (5.3)               3 (2.5)               0.56        6 (3.0)             4 (5.4)             0.47
  **Secondary end point, n (%)**   2 (4.7)               13 (11.5)             19 (15.8)             0.15        15 (7.4)            19 (25.7)           0.0001

**Note:**

The cutoff of 1.13 nmol/L was the threshold of MR-proADM providing the best combination of sensitivity and specificity for the occurrence of the primary end point.

**Abbreviations:** ECOPD, exacerbation of COPD; ICU, intensive care unit; MR-proADM, mid-regional pro-adrenomedullin.

###### 

Multivariate logistic regression to predict the occurrence of the primary and secondary end points

  Biomarkers and outcomes   Primary outcome   *P*-value    Secondary outcome   *P*-value                 
  ------------------------- ----------------- ------------ ------------------- ----------- ------------- -------
  MR-proADM (nmol/L)        1.65              1.10--2.48   0.015               1.99        1.27--3.11    0.002
  Clinical risk score                                                                                    
   Low                      1                 --           --                  1           --            --
   Medium                   1.24              0.48--3.18   0.64                2.17        0.46--10.10   0.33
   High                     1.72              0.68--4.34   0.24                2.67        0.57--12.39   0.21

**Note:** Models including MR-proADM and clinical risk score category.

**Abbreviations:** CI, confidence interval; MR-proADM, mid-regional pro-adrenomedullin; OR, odds ratio.

###### 

Multivariate logistic regression to predict the occurrence of the primary and secondary end points

  Biomarkers and outcomes   Primary outcome   *P*-value    Secondary outcome   *P*-value                 
  ------------------------- ----------------- ------------ ------------------- ----------- ------------- -------
  Copeptin, pmol/L          1.04              0.99--1.09   0.09                1.08        1.02--1.14    0.006
  Clinical risk score                                                                                    
   Low                      1                 --           --                  1           --            --
   Medium                   1.4               0.55--3.53   0.48                2.55        0.55--11.85   0.23
   High                     1.95              0.78--4.83   0.15                3.10        0.68--14.20   0.14

**Note:** Models including copeptin and clinical risk score category.

**Abbreviations:** CI, confidence interval; OR, odds ratio.
